We are live on ! Find out more
PLX icon

Protalix BioTherapeutics
PLX

31 hedge funds and large institutions have $2.45M invested in Protalix BioTherapeutics in 2021 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 7 increasing their positions, 10 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

3.23% less ownership

Funds ownership: 9.68% → 6.45% (-3.2%)

9% less funds holding

Funds holding: 34 → 31 (-3)

27% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 11

30% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 10

56% less capital invested

Capital invested by funds: $5.61M → $2.45M (-$3.16M)

77% less call options, than puts

Call options by funds: $140K | Put options by funds: $614K

Holders
31
Holders Change
-3
Holders Change %
-8.82%
% of All Funds
0.48%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
7
Reduced
10
Closed
11
Calls
$140K
Puts
$614K
Net Calls
-$474K
Net Calls Change
-$628K

Top Buyers

Rank Fund Capital Flow
1
Group One Trading
Group One Trading
Illinois
+$427K
2
SWM
Spire Wealth Management
Virginia
+$113K
3
Two Sigma Advisers
Two Sigma Advisers
New York
+$89.8K
4
Jane Street
Jane Street
New York
+$46.8K
5
Commonwealth Equity Services
Commonwealth Equity Services
Massachusetts
+$42.2K

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$1.04M
2
MIH
Meitav Investment House
Israel
-$325K
3
GCP
GSA Capital Partners
United Kingdom
-$241K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$177K
5
Walleye Trading
Walleye Trading
New York
-$108K
Name Holding Trade Value Shares
Change 		Change in
Stake
FDCDDQ
26
Federation des caisses Desjardins du Quebec
Quebec, Canada
$915 – – –
MIH
27
Meitav Investment House
Israel
– -$325K -244,332 Closed
Walleye Capital
28
Walleye Capital
New York
– -$293 -220,089 Closed
Walleye Trading
29
Walleye Trading
New York
– -$108K -81,000 Closed
Simplex Trading
30
Simplex Trading
Illinois
– -$72.3K -69,049 Closed
BCM
31
Bridgeway Capital Management
Texas
– -$78K -58,890 Closed
CS
32
Credit Suisse
Switzerland
– -$43K -31,974 Closed
Wolverine Trading
33
Wolverine Trading
Illinois
– -$29.5K -28,168 Closed
XT
34
XTX Topco
Cayman Islands
– -$27K -20,514 Closed
JP Morgan Chase
35
JP Morgan Chase
New York
– -$8K -5,847 Closed
HI
36
Harbour Investments
Wisconsin
– -$4K -3,000 Closed
UBS Group
37
UBS Group
Switzerland
– -$2.3K -2,194 -95%
SPIA
38
Steward Partners Investment Advisory
New York
– -$1K -1,000 Closed
TRCT
39
Tower Research Capital (TRC)
New York
– +$75 +72 New
RI
40
Rinkey Investments
California
– +$105 +100 New
SCA
41
Snowden Capital Advisors
New York
– +$524 +500 New
1
2

PLX Hedge Fund Activity: Q4 2021 in Review

31 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Protalix BioTherapeutics (PLX) for Q4 2021, worth a combined $2.45M — down 56% from $5.61M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of PLX and 8 opened new positions — a net loss of 3 holders — while 10 trimmed existing stakes and 7 added.

The largest buyer was Group One Trading, adding an estimated $427K. The largest seller was Morgan Stanley, cutting an estimated $1.04M.

  • 31 institutional investors held Protalix BioTherapeutics (PLX) as of Q4 2021, down from 34 in Q3 2021.
  • Funds reported $2.45M of Protalix BioTherapeutics stock for Q4 2021, down 56% quarter-over-quarter.
  • 8 funds opened new Protalix BioTherapeutics positions in Q4 2021 and 11 closed out, a net change of -3 holders.
  • The largest Protalix BioTherapeutics buyer in Q4 2021 was Group One Trading, an estimated $427K added.
  • The largest Protalix BioTherapeutics seller in Q4 2021 was Morgan Stanley, an estimated $1.04M sold.

Based on aggregated 13F filings for Q4 2021.